Tudorza Reduces COPD Flare-ups Without Increasing Risk of Cardiovascular Complications or Death, Phase 4 Trial Shows

Tudorza (aclidinium bromide) reduces flare-ups in patients with moderate to severe chronic obstructive pulmonary disease (COPD) without increasing the risk of cardiovascular complications such as heart attack and stroke, or death, data from a Phase 4 trial show. The findings were discussed by Robert Wise, MD,…

Circassia Adding Cardiovascular Safety Data on Tudorza Label for COPD Patients

The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for the addition of new clinical data on on the label of Tudorza (aclidinium bromide), a bronchodilator for the long-term treatment of chronic obstructive pulmonary disease (COPD) marketed by Circassia Pharmaceuticals…

Phase 4 Trial Finds Tudorza Safe and Effective for COPD Patients with Cardiovascular Disease

Long-term use of Tudorza (aclidinium bromide) can significantly and safely reduce exacerbations in people with moderate to severe chronic obstructive pulmonary disease and cardiovascular disease or risk factors, findings in a Phase 4 post-marketing study show. Tudorza, developed by AstraZeneca, contains the long-acting muscarinic antagonist (LAMA) aclidinium bromide,…

AstraZeneca and Circassia Partnering on COPD Inhalants

AstraZeneca and Circassia are partnering to develop and commercialize two inhaled respiratory treatments for chronic obstructive pulmonary disease (COPD) in the United States, Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide). Tudorza was approved by the U.S. Food and Drug Administration (FDA) in 2012, and its marketing began that…